2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163276
    OX2R-IN-2
    OX2R-IN-2 (compound 63c) is an agonist for orexin receptor type 2 (OX2R) with EC50 of 339 nM. OX2R-IN-2 is able to cross the blood-brain barrier and exhibits no cytotoxicity in cells
    OX2R-IN-2
  • HY-163280
    JGB-1-155 3011930-28-9
    JGB-1-155 is a positive allosteric modulators (N-PAMs), which enhances the activity of nicotinamide phosphoribosyltransferase NAMPT with EC50 of 3.29 μM. JGB-1-155 counteracts the oxidative stress, through upregulating the NAD+ in THP-1 human monocytes. JGB-1-155 attenuates TNFα-induced ROS in HT-22 cells .
    JGB-1-155
  • HY-163283
    6′-Methyl paeonol 6540-66-5
    6’-Methyl paeonol is a paeonol derivative, which inihibits abnormal depolarizations and reduces the Amyloid β-induced ERK phosphorylation. 6’-Methyl paeonol exhibits alleviating activity against Alzheimer’s Disease.
    6′-Methyl paeonol
  • HY-163320
    AChE/Aβ-IN-5 181114-32-9
    AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice.
    AChE/Aβ-IN-5
  • HY-163322
    MAO-A inhibitor 2
    MAO-A inhibitor 2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC50 of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research.
    MAO-A inhibitor 2
  • HY-163327
    pFBC
    pFBC ([18F]pEBC) is a covalent CLIP-tag radiotracer for detection of viral reporter gene transfer in the murine brain. pFBC can be used in neurobiological research.
    pFBC
  • HY-163329
    BCH-HSP-C01
    BCH-HSP-C01 is a lead compound that restores AP-4-dependent protein trafficking in neuronal models of adapter protein complex 4 (AP-4)-associated hereditary spastic paraplegia. BCH-HSP-C01 can be used for the research of autophagy-associated diseases.
    BCH-HSP-C01
  • HY-163345
    5-HT7R antagonist 2 1448808-50-1
    5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment.
    5-HT7R antagonist 2
  • HY-163349
    TUG-2099
    TUG-2099 (compound 4s) is a potent GPR84 agonist with the EC50 of 0.3 nM. TUG-2099 can be used for study of Alzheimer’s disease, atherosclerosis, cancer, and so an.
    TUG-2099
  • HY-163370
    HIF-1α-IN-7 3026685-76-4
    HIF-1α-IN-7 (Compound D13) is a potent HIF-1α inhibitor. HIF-1α-IN-7 has neuroprotective activity. HIF-1α-IN-7 can be used in Alzheimer's disease research.
    HIF-1α-IN-7
  • HY-163380
    CA/MAO-B-IN-1 98.34%
    CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction.
    CA/MAO-B-IN-1
  • HY-163382
    Cbz-Gly-Pro-Ala-O-cinnamyl
    Cbz-Gly-Pro-Ala-O-cinnamyl (compound 25) is a small peptide targeting BACE-1 and AChE with the IC50 values of 0.02 μM and 1 μM, respectively. Cbz-Gly-Pro-Ala-O-cinnamyl shows neuroprotective effect and can be used for study of Alzheimer’s disease.
    Cbz-Gly-Pro-Ala-O-cinnamyl
  • HY-163394
    CB2 receptor agonist 6
    CB2 receptor agonist 6 (compound 70) is an agonist of CB2R, with EC50 of 162 nM. The IC50 values of CB2 receptor agonist 6 are 4.83 μM for CB1R and 0.88 μM for CB2R. CB2 receptor agonist 6 is a neuroprotective agent that can be used for the reseach of neurological disease.
    CB2 receptor agonist 6
  • HY-163415
    MAO-IN-5 906728-07-2
    MAO-IN-5 (Compound ZINC000016952895) is a monoamine oxidase (MAO) inhibitor. According to the prediction of Swiss ADME, MAO-IN-5 can inhibit the CYP enzyme family, has blood-brain barrier (BBB) permeability, and has a high gastrointestinal absorption rate. MAO-IN-5 can be used in the study of neurological diseases.
    MAO-IN-5
  • HY-163441
    BChE-IN-31
    BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC50 of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide.
    BChE-IN-31
  • HY-163455
    pan-HCN-IN-1 1334308-63-2
    pan-HCN-IN-1 (Compound J&J12e) is an inhibitor for hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channel, with IC50 of 58 nM. pan-HCN-IN-1 reduces the voltage sag response and enhances EPSP summation in ex vivo rats brain slices.
    pan-HCN-IN-1
  • HY-163465
    DTNP 3010266-66-4
    DTNP is a BchE -activated near infrared (NIR) probe with blood-brain permeability. DTNP can be activated by BchE and inhibit its enzyme activity. DTNP can be used in Alzheimer's disease (AD) research.
    DTNP
  • HY-163474
    MAO-B-IN-32
    MAO-B-IN-32 is an inhibitor of MAO-B (IC50 = 16 nM).MAO-B-IN-32 increases dopamine concentration in the brain by inhibiting MAO-B activity.
    MAO-B-IN-32
  • HY-163497
    NLRP3-IN-38 3033054-46-2
    NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM.
    NLRP3-IN-38
  • HY-163498
    NLRP3-IN-37 3033054-51-9
    NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury.
    NLRP3-IN-37
Cat. No. Product Name / Synonyms Application Reactivity